'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors

被引:169
作者
Abdul-Rasoul, M [1 ]
Habib, H [1 ]
Al-Khouly, M [1 ]
机构
[1] Farwaniya Hosp, Dept Pediat, Endocrine Unit, Farwaniya, Kuwait
关键词
blood sugar; honeymoon phase; KA; partial remission; type 1 diabetes mellitus;
D O I
10.1111/j.1399-543X.2006.00155.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The honeymoon period (i.e., partial remission) of type 1 diabetes mellitus is characterized by reduced insulin requirements while good glycemic control is maintained. The clinical significance is the potential possibility for pharmacological intervention during this period to either slow down or arrest the ongoing destruction of the remaining beta-cells. Methods: A group of 103 diabetic children, younger than 12 yr of age, were prospectively studied to assess the frequency, duration, and factors that may affect partial remission. At the time of admission, patients were characterized by age, gender, symptom duration, diabetic ketoacidosis (DKA), and blood sugar level at admission. The honeymoon period was defined as a period with insulin requirements of less than 0.5 U/kg/day and hemoglobin A1c (HbA1c) level of less or equal to 6%. Results: Partial remission occurred in 71, being complete in three. The length of time until remission was 28.6 +/- 12.3 (mean +/- SD) days. The duration of remission was 7.2 +/- 4.8 months. Remission rates were higher in those patients older than 5 yr compared with those between 3 and 5 yr of age. DKA at presentation and long duration of symptoms were associated with lower duration of remission (p < 0.001 and p < 0.001, respectively). Children in whom remission occurred had significantly lower blood glucose levels and higher pH at presentation (p < 0.001 and p < 0.001, respectively). Conclusions: Young age and severe disease at presentation are associated with decreased residual beta-cells function that is reflected by a lower incidence of partial remission. These observations are important to consider in the research regarding therapies that will have the potential goal to induce prolonged and/or complete remission at disease onset or shortly thereafter.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 33 条
[21]   NATURAL COURSE OF REMISSION IN IDDM DURING 1ST YR AFTER DIAGNOSIS [J].
MARTIN, S ;
PAWLOWSKI, B ;
GREULICH, B ;
ZIEGLER, AG ;
MANDRUPOULSEN, T ;
MAHON, J .
DIABETES CARE, 1992, 15 (01) :66-74
[22]   Partial remission phase of diabetes in children younger than age 10 years [J].
Muhammad, J ;
Swift, PGF ;
Raymond, NT ;
Botha, JL .
ARCHIVES OF DISEASE IN CHILDHOOD, 1999, 80 (04) :367-369
[23]   Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM [J].
Ortqvist, E ;
Falorni, A ;
Scheynius, A ;
Persson, B ;
Lernmark, A .
ACTA PAEDIATRICA, 1997, 86 (11) :1166-1171
[24]   Is the process of β-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males? [J].
Pozzilli, P ;
Mesturino, CA ;
Crinò, A ;
Gross, TM ;
Jeng, LM ;
Visalli, N .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (06) :757-761
[25]   FACTORS PREDICTING COURSE OF BETA-CELL FUNCTION IN IDDM [J].
SCHIFFRIN, A ;
SUISSA, S ;
WEITZNER, G ;
POUSSIER, P ;
LALLA, D .
DIABETES CARE, 1992, 15 (08) :997-1001
[26]   RANDOMIZED PROSPECTIVE-STUDY OF SHORT-TERM AND LONG-TERM INITIAL STAY IN HOSPITAL BY CHILDREN WITH DIABETES-MELLITUS [J].
SIMELL, T ;
KAPRIO, EA ;
MAENPAA, J ;
TUOMINEN, J ;
SIMELL, O .
LANCET, 1991, 337 (8742) :656-660
[27]   HOMOGENEITY IN PATTERN OF DECLINE OF BETA-CELL FUNCTION IN IDDM - PROSPECTIVE-STUDY OF 204 CONSECUTIVE CASES FOLLOWED FOR 7.4 YR [J].
SNORGAARD, O ;
LASSEN, LH ;
BINDER, C .
DIABETES CARE, 1992, 15 (08) :1009-1013
[28]   FACTORS AFFECTING AND PATTERNS OF RESIDUAL INSULIN-SECRETION DURING THE 1ST YEAR OF TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS IN CHILDREN [J].
SOCHETT, EB ;
DANEMAN, D ;
CLARSON, C ;
EHRLICH, RM .
DIABETOLOGIA, 1987, 30 (07) :453-459
[29]   β-cell function and the development of diabetes-related complications in the diabetes control and complications trial [J].
Steffes, MW ;
Sibley, S ;
Jackson, M ;
Thomas, W .
DIABETES CARE, 2003, 26 (03) :832-836
[30]   Prognostic factors for the course of β cell function in autoimmune diabetes [J].
Törn, C ;
Landin-Olsson, M ;
Lernmark, Å ;
Palmer, JP ;
Arnqvist, HJ ;
Blohmé, G ;
Lithner, F ;
Littorin, B ;
Nyström, L ;
Scherstén, B ;
Sundkvist, G ;
Wibell, L ;
Östman, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12) :4619-4623